Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +91 more
Locations
  • Dignity Health St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Cancer Center Duarte, California, United States
  • City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services Duarte, California, United States
View all 130 locations
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Phoenix, Arizona, United States
  • Research Site Anaheim, California, United States
  • Research Site Berkeley, California, United States
  • Research Site Duarte, California, United States
View all 130 locations
View Trial Details
Active, Not Recruiting

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

NCT02159755

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Washington University School of Medicine St Louis, Missouri, United States
  • NYP/Weill Cornell Medical Center New York, United States
  • UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions
Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details
Active, Not Recruiting

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

NCT00846742

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • Packard Children's Hospital, Stanford University Palo Alto, California, United States
  • Rady Children's Hospital- San Diego San Diego, California, United States
  • Children's Hospital of Illinois at OSF St. Francis Medical Center Peoria, Illinois, United States
  • Maine Children's Cancer Program (MCCP) Scarborough, Maine, United States
View Trial Details
Active, Not Recruiting

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Indiana Blood and Marrow Transplantation Indianapolis, Indiana, United States
  • Community Health Network Cancer Center North Indianapolis, Indiana, United States
  • University of Kentucky Markey Cancer Center Lexington, Kentucky, United States
  • Henry Ford Health System Jackson, Michigan, United States
View all 186 locations
View Trial Details

Related conditions